A plausible explanation stems from a recently published paper suggesting that BNT162b2 administration elicited higher IgG and IgA titers compared to adenoviral vector AZD1222, thus providing mucosal immunity activation to prevent infection at oral and nasopharyngeal mucosa (47). Here, CD79A is linked to infection.